PMID- 32431542
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 12
DP  - 2020
TI  - MicroRNA-155 Suppresses the Translation of p38 and Impairs the Functioning of 
      Dendritic Cells in Endometrial Cancer Mice.
PG  - 2993-3002
LID - 10.2147/CMAR.S240926 [doi]
AB  - BACKGROUND: Dendritic cells (DCs) are reported to play an important role in 
      activating the anti-tumor immune responses. p38 MAPK14 signaling plays an 
      important role in controlling their activity. Here, we identified that miR-155 
      suppressed the translation of p38 and impaired the functioning of dendritic cells 
      in endometrial cancer. METHODS: HEC1A endometrial cancer cell lines were used for 
      the study which was transfected in the C57BL/6 mice. Murine bone marrow-derived 
      dendritic cells (BMDCs) were isolated from the mice. Target prediction was done 
      by TargetScan which was confirmed by RT-PCR analysis. The protein expression was 
      carried by Western blot analysis. Levels of IL-12 were evaluated by ELISA. Mice 
      injected with HEC1A cells were subjected to tumor challenge study. RESULTS: On 
      screening the binding sites of p38 MAPK14 gene, miR-155 was found to bind the 
      3'UTR directly and blocked its translation. The levels of miR-155 were 
      upregulated in dendritic cells and RAW264.7 cells, miR-155 showed inhibitory 
      effect on expression levels of p38. In dendritic cells, miR-155 was found to 
      regulate the expression of IL-12, also miR-155 inhibitor stimulated the 
      differentiation of Th1 cells in mice induced with endometrial cancer. In 
      dendritic cells, miR-155 inhibited the expression of p38 gene and decreased their 
      ability to interfere in tumor growth. CONCLUSION: The study concludes suppressive 
      role of miR-155 in the process of dendritic cells mediated anti-tumor immunity, 
      also inhibiting miR-155 provides a novel strategy for countering endometrial 
      cancer.
CI  - (c) 2020 Jia et al.
FAU - Jia, Jianjun
AU  - Jia J
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital, Jinan 
      University, Guangzhou 510632, People's Republic of China.
FAU - Li, Xiaomao
AU  - Li X
AD  - Department of Obstetrics and Gynecology, The Third Affiliated Hospital, Sun 
      Yat-Sen University, Guangzhou 510632, People's Republic of China.
FAU - Guo, Suiqun
AU  - Guo S
AD  - Department of Obstetrics and Gynecology, The Third Affiliated Hospital, Southern 
      Medical University, Guangzhou 510632, People's Republic of China.
FAU - Xie, Xingmei
AU  - Xie X
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital, Jinan 
      University, Guangzhou 510632, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20200430
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC7198441
OTO - NOTNLM
OT  - IL-12
OT  - RAW264.7 cells
OT  - dendritic cells
OT  - miR-155
OT  - p38
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/05/21 06:00
MHDA- 2020/05/21 06:01
PMCR- 2020/04/30
CRDT- 2020/05/21 06:00
PHST- 2019/12/03 00:00 [received]
PHST- 2020/03/31 00:00 [accepted]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/05/21 06:01 [medline]
PHST- 2020/04/30 00:00 [pmc-release]
AID - 240926 [pii]
AID - 10.2147/CMAR.S240926 [doi]
PST - epublish
SO  - Cancer Manag Res. 2020 Apr 30;12:2993-3002. doi: 10.2147/CMAR.S240926. 
      eCollection 2020.